Fortbildungsveranstaltungen, Publikationen Und Kongreßbeiträge 2006

Fortbildungsveranstaltungen, Publikationen und Kongreßbeiträge 2006:

Publikationen:

Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z. Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol. 2006 Dec;169(6):2199-208.

Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA, Culig Z. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene. 2006 Oct 30; .

Steiner H, Cavarretta IT, Moser PL, Berger AP, Bektic J, Dietrich H, Zaki MH, Nakada M, Hobisch A, Nemeth JA, Culig Z. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. Prostate. 2006 Dec 1;66(16):1744-52.

Steiner H, Gozzi C, Verdorfer I, Mikuz G, Bartsch G, Hobisch A. Metastatic spermatocytic seminoma--an extremely rare disease: Part 2. Eur Urol. 2006 Feb;49(2):408-9.

Steiner H, Gozzi C, Verdorfer I, Mikuz G, Bartsch G, Hobisch A. Metastatic spermatocytic seminoma--an extremely rare disease. Eur Urol. 2006 Jan;49(1):183-6. Epub 2005 Nov 8. Review.

Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate. 2006 Mar 1;66(4):413-20.

Berger AP, Deibl M, Strasak A, Bektic J, Pelzer A, Steiner H, Spranger R, Fritsche G, Bartsch G, Horninger W. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population. Urology. 2006 Nov;68(5):1067-71. Epub 2006 Nov 7.

Schwentner C, Oswald J, Lunacek A, Schlenck B, Berger AP, Deibl M, Fritsch H, Bartsch G, Radmayr C. Structural changes of the intravesical ureter in children with vesicoureteral reflux-does ischemia have a role? J Urol. 2006 Nov;176(5):2212-8.

Steiner H, Cavarretta IT, Moser PL, Berger AP, Bektic J, Dietrich H, Zaki MH, Nakada M, Hobisch A, Nemeth JA, Culig Z. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. Prostate. 2006 Dec 1;66(16):1744-52.

Bektic J, Guggenberger R, Spengler B, Christoffel V, Pelzer A, Berger AP, Ramoner R, Bartsch G, Klocker H. The flavonoid apigenin inhibits the proliferation of prostatic stromal cells via the MAPK-pathway and cell-cycle arrest in G1/S. Maturitas. 2006 Nov 1;55 Suppl 1:S37-46. Epub 2006 Aug 17.

Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G, Rantner B, Fraedrich G, Pallwein L, Aigner F, Horninger W, Frauscher F. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int. 2006 Nov;98(5):1038-42. Epub 2006 Jul 28.

Berger AP, Hager J. Management of neonates with large abdominal wall defects and undescended testis. Urology. 2006 Jul;68(1):175-8. Epub 2006 Jun 27.

Berger AP, Horninger W, Bektic J, Pelzer A, Spranger R, Bartsch G, Frauscher F. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease? BJU Int. 2006 Sep;98(3):587-90. Epub 2006 Jun 26.

Steiner H, Muller T, Gozzi C, Akkad T, Bartsch G, Berger AP. Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours. BJU Int. 2006 Aug;98(2):349-52. Epub 2006 Apr 18.

Pelzer AE, Bektic J, Haag P, Berger AP, Pycha A, Schafer G, Rogatsch H, Horninger W, Bartsch G, Klocker H. The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer. J Urol. 2006 Apr;175(4):1517-22. Abstracts - Kongressbeiträge:

Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A, Culig Z. “Androgens upregulate SOCS-3 protein in prostate cancer cell lines.” 16th Annual Meeting of the Society for Basic Urological Research (SBUR), Phoenix, 2006.

Cavarretta IT, Neuwirt H, Zaki MH, Steiner H, Hobisch A, Nemeth JA, Culig Z. “Mcl-1 is Regulated by IL-6 and Mediates the Survival Activity of the Cytokine in a Model of Late Stage Prostate Carcinoma.” 23rd Annual Meeting Hormonal Carcinogenesis Montpellier, 2006

Malinowska K, Cavarretta IT, Neuwirt H, Fuchs D, Hobisch A, Nemeth JA, Culig Z. “Interleukin-6 exerts different effects on proliferation and signal transduction in two androgen-sensitive prostate cancer cell lines.” 17th Meeting of the European Society for Urological Research (ESUR), Malmö, 2006

Neuwirt H, Bellezza I, Nemes C, Cavarretta IT, Steiner H, Offner F, Hobisch A, Minelli A, Bartsch G, Doppler W, Culig Z. “Suppressor of Cytokine Signaling-3 (SOCS-3), a Modulator of cAMP-Induced Growth Arrest and Apoptosis, Is Expressed in Prostate Carcinoma In Vitro and In Vivo.” Annual Meeting of the Endocrine Society, Boston, 2006

Cavarretta IT, Moser P, Untergasser G, Zaki M, Steiner H, Bartsch G, Hobisch A, Nemeth J, Culig Z: “The antiapoptotic effect of IL-6 in a cellular model of advanced prostate cancer is mediated by Mcl-1”, Annual Meeting of the Endocrine Society, Boston, 2006

Berger AP, Deibl M, Klocker H, Steiner H, Bektic J, Pelzer A, Leonhartsberger N, Bartsch G, Horninger W, Innsbruck, Austria Correlation of PSA-Velocity with tumor-stage and gleason score in a screening population, European Association of Urology Congress 2006 (05.04. – 08.04.2006), Paris

A safer way of transurethral resection of the prostate: coagulating intermittent cutting reduces hemostatic complications Berger AP, Pelzer A, Bektic J, Steiner H, Lunacek A, Bartsch G, Horninger W, Innsbruck, Austria, European Association of Urology Congress 2006 (05.04. – 08.04.2006), Paris

PSA-velocity depends on pathologic stage and gleason score even after biochemical failure after radical prostatectomy Berger AP, Deibl M, Klocker H, Steiner H, Tewari A, Bektic J, Pelzer A, Leonhartsberger N, Lunacek A, Bartsch G, Horninger W, Innsbruck, Austria, European Association of Urology Congress 2006 (05.04. – 08.04.2006), Paris

Adverse pathological findings in patients with needle biopsy gleason score 6 prostate cancer with a PSA level of 2-4 ng/ml and 4-10 ng/ml following radical prostatectomy Bektic J, Pelzer A, Berger AP, Bartsch G, Horninger W, Innsbruck, Austria, European Association of Urology Congress 2006 (05.04. – 08.04.2006), Paris Urethral gray-scale and color doppler sonography in the diagnostic evaluation of anterior urethral stricture Pelzer A, Bektic J, Berger AP, Pallwein L, Akkad T, Bartsch G, Horninger W, Innsbruck, Austria, European Association of Urology Congress 2006 (05.04. – 08.04.2006), Paris

PSA-velocity as a tool to identify organ confined prostate cancers in a screening population Berger AP, Deibl M, Klocker H, Bektic J, Tewari A, Pelzer A, Leonhartsberger N, Lunacek A, Steiner H, Bartsch G, Horninger W, Innsbruck, Austria, New York, USA, American Urological Association Congress (20.05. – 25.05.2006), Atlanta

Urethral gray-scale and color doppler sonography in the diagnostic evaluation of anterior urethral stricture Pelzer A, Gozzi C, Radmayr C, Pallwein L, Bektic J, Berger AP, Bartsch G, Frauscher F, Innsbruck, Austria, American Urological Association Congress (20.05. – 25.05.2006), Atlanta

Is there a normal PSA value? Horninger W, Severi G, Berger AP, Oberaigner W, Tewari A, Robertson C, Bartsch G, Boyle P, Innsbruck, Austria, Milan, Italy, New York, USA, American Urological Association Congress (20.05. – 25.05.2006), Atlanta

PSA does not discover low stage and low grade prostate cancers Horninger W, Berger AP, Pelzer A, Bektic J, Tewari A, Klocker H, Bartsch G, Innsbruck, Austria, New York, USA, American Urological Association Congress (20.05. – 25.05.2006), Atlanta

Prostate cancer detection rate and changes in gleason score in regard to patients age: 12 year experience Bektic J, Berger AP, Pelzer A, Bartsch G, Horninger W, Innsbruck, Austria, American Urological Association Congress (20.05. – 25.05.2006), Atlanta

Comparison of real-time elastography targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection Frauscer F, Pallwein L, Aigner F, Berger AP, Pelzer A, Horninger W, Bartsch G, Innsbruck, Austria, American Urological Association Congress (20.05. – 25.05.2006), Atlanta

Age-related rhabdosphincter function in female urinary stress incontinence: assessment of intraurethral ultrasonography Gradl J, Pallwein L, Klauser A, Berger AP, Strasser H, Bartsch G, Frauscher F, Innsbruck, Austria, American Urological Association Congress (20.05. – 25.05.2006), Atlanta

A safer way of transurethral resection of the prostate: coagulating intermittent cutting reduces hemostatic complications Berger AP, Pelzer A, Bektic J, Steiner H, Lunacek A, Tewari A, Bartsch G, Horninger W, Innsbruck, Austria, New York, USA, American Urological Association Congress (20.05. – 25.05.2006), Atlanta

PSA-velocity depends on tumor volume but not on prostate volume Berger AP, Pelzer A, Bektic J, Steiner H, Lunacek A, Bartsch G, Horninger W, Innsbruck, Austria, American Urological Association Congress (20.05. – 25.05.2006), Atlanta PSA-velocity increases continuously in the years prior to diagnosis of prostate cancer Berger AP, Deibl M, Klocker H, Steiner H, Bektic J, Pelzer A, Lunacek A, Bartsch G, Catalona W, Horninger W, Innsbruck, Austria, Chicago, USA, American Urological Association Congress (20.05. – 25.05.2006), Atlanta

PSA-velocity als hilfsmittel zur unterscheidung organbegrenzter versus nichtorganbegrenzter prostatakarzinome in einer screeningpopulation Berger AP, Deibl M, Klocker H, Bektic J, Pelzer A, Bartsch G, Horninger W, Innsbruck, Austria, Alpenländisches Urologensymposium (29.03. – 01.04.2006), Wagrain

PSA-Velocity als Hilfsmittel zur Unterscheidung von benignen und malignen Prostatae Berger AP, Feldkirch, Austria, Tagung der AUO (28.10.2006), Salzburg

Lehrtätigkeit:

Lehrauftrag an der Gesunden- und Krankenpflegeschule Feldkirch: 16 Unterrichtsstunden Urologie

12.10.2006 Palliativlehrgang Batschuns: Unterrichtstätigkeit im Rahmen des Palliativlehrgangs Macht und Ohnmacht: heilendes Umgehen mit Patienten und mit uns selbst.

Vorträge + Fortbildungen:

10.01.2006 Aula LKH Feldkirch: 1. Kinderurologische Fortbildung: „Neugeborenenhydronephrose und vesikorenaler Reflux“ Prim. Doz. Dr. Marcus Riccabona ( KH der barmherzigen Schwester Linz, Abteilung für Kinderurologie OÄ Dr. Ruth Krumpholz (LKH Feldkirch, Abteilung für Anästhesie und Intensivmedizin) Dr. Ariane Bibl (LKH Feldkirch, Abteilung für Pädiatrie) OÄ Dr. Saskia Pfefferkorn (LKH Feldkirch, Abteilung für Urologie)

2/06 Einführung in die Biologie des Prostatakarzinoms für Mitglieder der Vorarlberger Selbsthilfe Prostatakrebs. Prim. Univ. Doz. Dr. Alfred Hobisch:

13.03.06 Fortbildung Vorarlberger Selbsthilfe Prostatakrebs: St Arbogast Macht und Ohnmacht, Umgang mit kranken Patienten Prim. Univ. Doz. Dr. Alfred Hobisch

19.04.06 Haus Gisingen, Karnkenpflegeverein Gisingen: Macht und Ohnmacht im Umgang mit kranken Mitmenschen Prim. Univ. Doz. Dr. Alfred Hobisch

25.04.06 Institut für Pathologie Feldkirch: Die Biologie des Androgenrezeptors und mögliche Wege zur Überwindung der Androgenresistenz Prim. Univ. Doz. Dr. Alfred Hobisch

5/06 Martinspark Dornbirn Moderation: Prostatakarzinom im fortgeschrittenen Stadium, Therapiemöglichkeiten mit Bicalutamid Prim. Univ. Doz. Dr. Alfred Hobisch

5/06 Am Bach, Götzis: Prostatakarzinom - Vorsorge Prim. Univ. Doz. Dr. Alfred Hobisch

4.07.06 Panoramahaus Dornbirn: Fortschritte in der Therapie beim metastasierten Nierenzellkarzinom Prim. Univ. Doz. Dr. Alfred Hobisch

03.10.06 Qualitätssicherungprojekt der Urologie am LKH Feldkirch: Handbuch „für den guten Umgang mit Patienten“ Prim. Univ. Doz. Dr. Alfred Hobisch

24.10.06 onkologische Fortbildung Panoramahaus Dornbirn: Fortschritte in der Therapie des Nierenzellkarzinoms Prim. Univ. Doz. Dr. Alfred Hobisch

Krankenhausinterne Fortbildungen für urologisch interessiertes Personal:

21.02.06 Diagnostik in der Urologie Dr. Christoph Berger, Dr. Patrick Rein

25.04.06 palliative Aspekte von schwerkranken uroonkologischen Patienten OA Dr. Otto Gehmacher LKH Hohenems

13.04.06 Vorstellung des neuen Pflegedokumentations-programmes N-Ca-Sol (Nursing Care Solution) DGKS Evelyn, DGKS Nicole, DGKS Annemarie, DGKS Angelika

17.10.06 Muskelinvasives Blasenkarzinom - Cystektomie und unterschiedliche Formen der Harnableitung Prim. Univ. Doz. Dr. Alfred Hobisch

Dissertationsbetreuung durch Prim. Univ. Doz. Dr. Alfred Hobisch:

Frau c.m. Victoria König Dissertationsthema: “Bladdercancer in kidney transplant recipient”